{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '77', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Hypophysitis', 'Grade 2', 'Withhold', 'Administer corticosteroids and initiate', 'Monitor for signs and symptoms of hypophysitis', 'hormonal replacements as clinically', '(including hypopituitarism and adrenal', 'indicated', 'insufficiency)', 'Grade 3 or 4', 'Withhold or', 'permanently', 'discontinue a', 'Hyperthyroidism', 'Grade 2', 'Continue', 'Treat with nonselective beta-blockers', 'Monitor for signs and symptoms of thyroid', '(eg, propranolol) or thionamides as', 'disorders', 'appropriate', 'Grade 3 or 4', 'Withhold or', 'Permanently', 'discontinue a', 'Hypothyroidism', 'Grade 2-4', 'Continue', 'Initiate thyroid replacement hormones', 'Monitor for signs and symptoms of thyroid', '(eg, levothyroxine or liothyronine)', 'disorders', 'per standard of care', 'Nephritis and', 'Grade 2', 'Withhold', 'Administer corticosteroids (prednisone', 'Monitor changes of renal function', 'renal dysfunction', '1-2 mg/kg or equivalent) followed', 'Grade 3 or 4', 'Permanently', 'by taper', 'discontinue', 'Myocarditis', 'Grade 1', 'Withhold', 'Based on severity of AE administer', 'Ensure adequate evaluation to confirm etiology', 'corticosteroids', 'and/or exclude other causes', 'Grade 2, 3 or 4', 'Permanently', 'discontinue', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '78', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'All Other irAEs', 'Persistent Grade 2', 'Withhold', 'Based on severity of AE administer', 'Ensure adequate evaluation to confirm etiology or', 'corticosteroids', 'exclude other causes', 'Grade 3', 'Withhold or', 'discontinue b', 'Recurrent Grade 3', 'Permanently', 'or Grade 4', 'discontinue', 'AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash', 'with Eosinophilia and Systemic Symptom; Gl=gastrointestinal; 10=immuno-oncology; ir=immune-related; IV=intravenous; SJS=Stevens-Johnson Syndrome; T1DM=type 1', 'diabetes mellitus; TEN=Toxic Epidermal Necrolysis; ULN=upper limit of normal.', 'Note: Non-irAE will be managed as appropriate, following clinical practice recommendations.', 'a The decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the investigator or treating', 'physician. If control achieved or VI Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.', 'b', 'Events that require discontinuation include, but are not limited to: Guillain-Barre Syndrome, encephalitis, myelitis, DRESS, SJS, TEN and other clinically', 'important', 'irAEs', '(eg, vasculitis and sclerosing cholangitis).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}